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Transcatheter aortic valve implantation (TAVI) is a less invasive procedure to treat severe aortic valve stenosis than 
conventional surgical aortic valve replacement. Furthermore, TAVI has shown similar clinical outcomes as surgical 
treatment with less mortality and morbidities in elderly patients at high risk for conventional surgery. In this report, we 
describe case of successful TAVI using a CoreValve in a 103-year-old patient with symptomatic severe aortic valve 
stenosis.
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INTRODUCTION
Aortic stenosis (AS) is the most common cause for ob-
struction of flow from the left ventricle into the aorta. 
It is present in 2% of those with age over 65 years and 
4% of those with age over 85 years. Among various heart- 
valve diseases, AS is the most commonly acquired native 
valve disease afflicting the elderly population in western 
countries. As the Korean population is growing older, the 
prevalence of degenerative AS among the elderly in Korea 
is also increasing. Until recently, the standard treatment 
of severe AS has been surgical replacement of aortic valve. 
However, comorbidities and old age are associated with 
advanced procedure-related morbidity and mortality rates. 
About one third of patients with severe AS and older than 
75 years are not referred to a surgeon because of the 
high surgical risk1).
The development of a catheter-based therapy for heart 
valve disease is rapidly evolving, especially in AS. Trans- 
catheter aortic valve implantation (TAVI) allows the repla- 
cement of aortic valve without asternotomy or cardiopul- 
monary support. In this report, we describe a 103-year- 
old Korean patient treated by TAVI using a CoreValve 
(Medtronic, Minneapolis, MN, USA).
CASE REPORT
A 103-year-old male presented with dyspnea, cough 
and pinkish sputum. The patient had a history of hyper-
tension and coronary artery disease with previous stent 
insertion at right coronary artery 5 years ago. He had 
been diagnosed with severe AS and came to our hospital 
for consideration of TAVI. On admission his blood pres-
sure and pulse rate were 145/51 mmHg and 98/min. His 
body weight and height was 42.1 kg and 150 cm, respec- 
tively. The 12-lead electrocardiogram (ECG) on admission 
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Fig. 1. (A) Transthoracic echocardiogram with a parasternal
long axis view of the aortic valve. Sclerocalcifiedstenotic aortic
valve before TAVI (arrow). (B) Implanted CoreValve after 
TAVI (arrowheads). (C) Doppler echocardiogram showing 
severe aortic stenosis with turbulence across the valve before
TAVI (peak systolic pressuregradient of 109 mmHg). (D) After
TAVI (peak systolic pressuregradient of 17 mmHg). LA, left
atrium; LV, left ventricle; RV, right ventricle; TAVI, trans-
catheter aortic valve implantation.
Fig. 2. Fluoroscopic image 
of the CoreValve positioned
within the aortic valve.
showed sinus rhythm with right bundle branch block and 
findings suggestive of left ventricular hypertrophy with 
strain on lateral leads. Cardiomegaly and nodular opacity 
in right apex and hilum were noted on the chest x-ray. 
Transthoracic echocardiography revealed severe degen-
erative change of aortic valve with severe calcification
(Fig. 1A, C). The aortic valve area was 0.36 cm2 with a 
mean systolic pressure gradient of 65 mmHg and peak 
systolic pressure gradient of 109 mmHg compatible with 
severe AS. The left ventricular end diastolic and systolic 
diameter were 48 and 38 mm with slightly reduced sys-
tolic function (ejection fraction 47%). There was mild pul-
monary hypertension with an estimated right ventricular 
systolic pressure of 37 mmHg. Computed tomography (CT) 
images demonstrated heavily calcified aortic valve with 
annulus diameter ranging from 22 to 30 mm and annulus 
perimeter of 80.6 mm. The CT angiography demonstrated 
iliac arteries with minimum diameter of greater than 6.5
mm and common femoral arteries with minimum diame-
ter of greater than 7.5 mm on both sides. There was no 
significant stenosis or calcification in iliac and common 
femoral arteries. Coronary angiography showed 90% in- 
stent restenosis of previously implanted stent at right cor-
onary artery ostium. A pulmonary function test revealed 
no obstructive airway disease. A multidisciplinary heart 
team consisted of interventional cardiologists, cardiac sur- 
geons, anesthesiologists and imaging specialists evalua- 
ted the case and approved TAVI in this patient.
The procedure was carried out in a hybrid operating 
room under general anesthesia. Before TAVI procedure, 
in-stent restenosis of the proximal right coronary artery 
was first treated successfully with balloon angioplasty via 
the right common femoral artery (CFA). The vascular ac-
cess for the 18-Fr CoreValve delivery catheter was obtai- 
ned at the left CFA with standard percutaneous access 
techniques. A 6-Fr introducer sheath was inserted through 
the left CFA after preparing percutaneous closure using 
two preloaded suture devices (Perclose Proglide, Abbott 
Laboratories, Abbott Park, IL, USA). A pigtail catheter was 
inserted through the right CFA and positioned at the aortic 
root for the aortography during the procedure. A 0.032 
inch wire was passed through the aortic valve into the 
left ventricle using an AL1 catheter. The AL1 catheter was 
exchanged to a pigtail catheter. A 0.035 inch preshaped 
superstiff wire was inserted in the left ventricle through 
pigtail catheter. The 6-Fr introducer sheath was exchan- 
ged to a 18-Fr sheath. A 29-mm CoreValve was loaded 
in a delivery catheter and the delivery catheter was inser- 
ted through the 18-Fr sheath into the aortic valve. Under 
angiographic guidance, the CoreValve was positioned 
within the aortic valve and slowly deployed (Fig. 2). After 
CoreValve deployment, transesophageal echocardiogra- 
phy (TEE) showed moderate degree of paravalvular leak. 
Therefore, postdilation was performed using a 25×40
mm balloon (Maxi, Cordis, Diegem, Belgium) during rapid 
right ventricular pacing. Final postprocedural TEE dem-
onstrated a mild-to-moderate degree of paravalvular leak. 
The vascular access site for TAVI was closed by tighten-
ing the Perclose knots. The procedure was completed wit- 
hout complications.
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After the procedure, the patient was observed in an 
intensive careunit with continuous ECG monitoring and 
temporary pacemaker back-up. The follow-up transthora- 
cic echocardiography showed the well functioning bio-
prosthetic aortic valve (Fig. 1B, D) with reduced peak 
and mean pressure gradient over the aortic valve 17 and 
9 mmHg, respectively. No significant conduction abnor-
malities were observed except for intermittent complete 
atrio-ventricular block. The patient was discharged from 
the hospital at day 8 post procedure.
DISCUSSION
This is the case of the oldest patient in Korea who un-
derwent TAVI procedure so far. The current indications 
for TAVI are as follows: (1) severe AS (aortic valve area: 
<1 cm2, mean pressure gradient >40 mmHg, severe sym- 
ptoms); (2) contraindication for surgical valve replace- 
ment. The contraindications for TAVI areas follows: (1) 
mild to moderate AS; (2) asymptomatic patients; (3) life 
expectancy <1 year; (4) surgical aortic valve replacement 
possible, but patient refused; (5) aortic annulus <18 or 
>25 mm (ballon-expandable) and <20 or >27 mm (selfex- 
pandable); (6) bicuspid aortic valve; (7) asymmetric 
heavy valvular calcification; (8) Aortic root >45 mm at the 
aortotubular junction; (9) presence of left ventricular ap-
ical thrombus2). In addition, patient’s general condition 
and comorbities should also be taken into consideration. 
It is common that very old patients have multiple comor- 
bities over all kinds of organs. Although our patient was 
over 100 years old and had symptomatic severe AS, he 
was able to ambulate without assistance and had no 
mental problems such as dementia. Therefore, our multi-
disciplinary cardiovascular team decided to proceed with 
TAVI instead of surgery or medical treatment.
Treatment with TAVI is generally associated with lower 
rates of death from any cause, as compared with stand-
ard therapy. The PARTNER (Placement of AoRTictraNs- 
cathetER valves) trial3,4) has evaluated the transcatheter 
aortic valve replacement in patients with AS who are 
considered either high risk (Cohort A, 699 patients) or in-
operable (Cohort B, 358 patients) for conventional open- 
heart surgery. Thirty-day mortality for PARTNER A was 
3.4% for transcatheter aortic valve replacement and 6.5% 
for aortic valve replacement; 1-year mortality was 24.2% 
and 26.8% (p=0.001), respectively. For PARTNER B, thir-
ty-day mortality was 5.0% for transcatheter aortic valve 
replacement and 2.8% for medical treatment; 1-year mor-
tality was 30.7% vs. 50.7% (p<0.001), respectively. In ad-
dition to decrease in mortality and morbidity, TAVI pro-
cedures improved clinical symptoms and physical per- 
formance. Grimaldi et al.5) assessed the improvement of 
quality of life (QoL) in 145 octogenarians who underwent 
TAVI for AS or isolated AR instead of surgery since their 
comorbities were unacceptable for surgery. QoL was as-
sessed by questionnaires concerning physical and psy-
chic performance. As a result, 49% walked an-assisted, 
79% reported self-awareness improvement; QoL was re-
ported as “good” in 58%, “acceptable according to age” 
in 34% and “bad” in 8%.
Currently, self-expanding CoreValve and balloon-ex-
panding SAPIEN valve are widely used for TAVI proce- 
dure. Although there has been no randomized compar-
ison study between these two bioprosthetic valves, tech-
nical success rates and major clinical outcomes appeared 
to be similar except for conduction disorders such as left 
bundle branch or atrio-ventricular block and pacemaker 
implantation (20-30% versus 3-5%) which are more fre-
quently observed in patients treated with the CoreValve 
versus SAPIEN valve6-10). The two valves have totally dif-
ferent deployment methods. Whereas SAPIEN valve is 
deployed with instant balloon inflation, CoreValve is in-
serted by slow release for self-expansion with more 
room for adjustment. The choice of the valve is currently 
more dependent on the operator’s technical preference. 
In our case, the patient was discharged from the hospital 
at day 8 post TAVI without significant complication ex-
cept for the transient atrio-ventricular block. His dyspnea 
symptom has been significantly improved after the pro- 
cedure.
In summary, this is the case of the oldest patient in 
Korea with severe AS who has been successfully treated 
by TAVI. In very elderly patients at high risk for conven-
tional surgery, TAVI appears to be an effective and safe 
alternative treatment modality3,4,11,12).
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